Journey Medical's Emrosi shows superior efficacy in rosacea treatment.

FDA-approved Emrosi, a low-dose minocycline formulation, demonstrated superior efficacy in treating inflammatory lesions of rosacea in adults compared to placebo and doxycycline in a pooled analysis of two Phase 3 trials. The results showed higher IGA success rates and reduced inflammatory lesion counts for Emrosi. Journey Medical Corporation presented the findings in a poster at a conference.